Cytoreductive Surgery(CRS) Plus Hyperthermic Intraoperative Peritoneal Chemotherapy(HIPC) With Cisplatin to Treat Peritoneal Carcinomatosis From Upper Gastrointestinal Cancer
NCT ID: NCT01116791
Last Updated: 2015-12-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
34 participants
INTERVENTIONAL
2010-07-31
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Primary tumour Biliary adenocarcinoma
* Intrahepatic cholangiocellular carcinoma \< 3 cm in diameter
* Extrahepatic cholangiocellular carcinoma without invasion of major blood vessels (portal vein, hepatic arteries, coeliac trunk) Gastric adenocarcinoma Macroscopic surgical margin of 5 cm is needed to obtain complete tumour removal Pancreatic adenocarcinoma Tumours located in the head, body or tail of the pancreas without portal hypertension due to complete encasement of mesenteric/portal vein and collateral venous circulation
* Liver metastases
* Only liver metastases with stable disease or clinical response to prior systemic therapy for a period of at least 3 months are eligible
* Not more than 3 metastases, each measuring 3 cm or less in diameter
* Solitary liver metastasis smaller than 5 cm in diameter located in the periphery of ventral segments (Sg 2-6)
* Peritoneal metastases
* Sugarbaker's peritoneal cancer index (PCI) will be used to assess peritoneal tumour burden 28. The completeness of cancer resection (CCR) will be assessed by the surgeon at the end of CRS; CCR-0 no macroscopic residual tumour, CCR-1 no residual tumour nodules greater than 2.5 mm, CCR-2 residual tumour nodules larger than 2.5 mm in diameter.
* Patients with PCI \< 20 are eligible for this study 11.
THERAPEUTIC INTERVENTION
* CRS is defined as macroscopic tumour removal using surgical resection and/or LAT
o Primary tumour Biliary adenocarcinoma
* Intrahepatic cholangiocellular carcinoma
* Deep parenchymatous tumours are treated by LAT
* Superficial peripheral tumours are treated by resection or LAT
* Distance between tumour and major biliary structures (right, left, main hepatic duct) needs to be \> 1 cm
* Extrahepatic cholangiocellular tumours are treated by surgical resection and biliodigestive reconstruction
* Distal cholangiocellular tumours with intrapancreatic location are treated by pancreaticoduodenectomy or LAT at 90°C
* Lymph nodes around the hepatoduodenal ligament are removed Gastric adenocarcinoma
* Partial gastrectomy can be performed either by proximal or distal gastrectomy dependent on tumour location and size
* Total gastrectomy is performed in patients with signet-ring cell cancers or linitis plastica
* Tumour-draining lymph nodes are removed Pancreatic adenocarcinoma
* Tumours located in the head of the pancreas and with radiologic or macroscopic vascular invasion, which need vascular reconstruction at the time of surgery, are treated by LAT at ablation temperature of 90°C
* Tumours located in the head of the pancreas without radiologic or macroscopic vascular invasion are treated by pancreaticoduodenectomy or LAT at 90°C
* Tumours located in the body or tail of the pancreas are treated by resection or LAT of 90°C
* Tumour draining lymph nodes are removed
o Liver metastases
* Tumours up to 3 cm are treated by LAT (RFA or MWA)
* Solitary tumour measuring 3 - 5 cm is treated by resection
* Superficial peripheral liver metastases (any diameter up to 5 cm) are allowed to be resected
o Peritoneal metastases
* Peritonectomy, electrofulguration of superficial (\< 3mm depth) metastases, and organ resection are allowed
* HIPC is administered immediately after CRS: cisplatin at a dose of 100 mg/m2 is dissolved in 3 litres of normal saline heated to less than 41° Celsius and infused into the abdominal cavity for a sustained hyperthermic intraperitoneal chemotherapy for 60 minutes. Surgical reconstruction (anastomoses) is performed after HIPC.
TRANSLATIONAL RESEARCH
1. Perioperative quantification of peritoneal and circulating tumour cells
* Real-time qRT-PCR based on detection and quantification of CEA and EpCAM mRNA transcripts
* Circulating tumour cells in peripheral blood samples will be studied before and at the end of surgical procedure (CRS+HIPC)
* Peritoneal tumour cells will be evaluated in lavage fluid at the start of surgery (before any manipulation) and at the end of CRS+HIPC
2. Perioperative systemic cytokine profiles and lymphocyte immunophenotyping
* Plasma concentration of cytokines will be determined using the BDTM Cytometric Bead Array (CBA): IL-1β, IL-2, IL-6, IL-8, IL-10, IL-12p70, IL-13, IFN-γ, and VEGF
* The relative proportions and absolute numbers B-lymphocytes (CD19+), T-lymphocytes (CD3+), NK cells (CD56+CD3-), effector T cells (CD3+CD4+ and CD3+CD8+), HLA-DR+ T cells (CD3+HLA-DR+) and regulatory T cells (CD3+CD4+25+127low) will be quantified with flow cytometry.
* Time-points for cytokine and immunophenotyping analyses: before surgery (d-1), at the end of surgery (d0), day after (d1) and at day 7 following CRS+HIPC
3. Gene-expression of primary and metastatic pancreatic cancer
* To better understand cancer biology and search for novel diagnostic and therapeutic targets, fresh tissue samples from the primary tumour and from metastases will be stored in RNA-later for RNA-extraction and future analyses. Hereto, samples obtained from biliary, gastric, and pancreatic cancer tissue will be stored. Based on the fact that pancreatic cancer is associated with the worst prognosis, and based on our ongoing research on this disease, gene expression studies in the current project will be focused on pancreatic cancer.
* In close collaboration with the department of pathology, we have stored snap-frozen tissue samples from surgically resected human pancreatic cancer for future research. Clinical, histopathological, and survival data of over 200 patients are registered in our database. Tissue samples (primary and metastases) from the current study will be analysed together with available 96 primary tumour samples that have already been controlled to be representative for high quality RNA studies. These samples are obtained from patients with early and advanced localized pancreatic cancer in various tumour stages. Gene-expression studies will be performed using Affymetrix HG U133 Plus 2.0 arrays on primary and metastatic tissue samples. These experiments will be conducted in close collaboration with the microarray facility of VIB at KUL.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CRS+HIPC
Patients with biliary, gastric, or pancreatic carcinoma and metastatic or recurrent disease confined to the abdominal compartment
Cytoreductive Surgery (CRS) plus Hyperthermic Intraoperative Peritoneal Chemotherapy with Cisplatin (HIPC)
* CRS is defined as macroscopic tumour removal using surgical resection and/or local ablative therapy (LAT)
* HIPC is administered immediately after CRS
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cytoreductive Surgery (CRS) plus Hyperthermic Intraoperative Peritoneal Chemotherapy with Cisplatin (HIPC)
* CRS is defined as macroscopic tumour removal using surgical resection and/or local ablative therapy (LAT)
* HIPC is administered immediately after CRS
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histological confirmation of primary (or recurrent) and metastatic disease
* Systemic chemotherapy and/or biological is allowed before and/or after CRS+HIPC
* Radiotherapy is allowed before or after CRS+HIPC
* Patients must not have failed prior intraperitoneal platinum-therapy
* Age between 18 to 75 years
* Patient Karnofsky performance scale (KPS) \> 80 (normal activity with a bit of effort)
Exclusion Criteria
* Pregnancy
* Any malignancy other than biliary, gastric, or pancreatic adenocarcinoma
* Any metastatic disease outside the abdominal compartment, such as pulmonary or bone metastases
* Peritoneal carcinomatosis index (PCI) \> 20 at the start of CRS
* Peritoneal residual tumour nodules larger than 2.5 mm after CRS (CCR-2)
* Clinical relevant ascites
* More than 3 liver metastases
* Solitary liver metastasis larger than 5 cm
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universitaire Ziekenhuizen KU Leuven
OTHER
Baki Topal
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Baki Topal
Professor of Surgery
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Baki Topal, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Universitaire Ziekenhuizen KU Leuven
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospitals Leuven
Leuven, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Topal B, Demey K, Topal H, Jaekers J, Van Cutsem E, Vandecaveye V, Sagaert X, Prenen H. Cytoreductive surgery and Hyperthermic intra-operative peritoneal chemotherapy with Cisplatin for gastric peritoneal Carcinomatosis Monocentric phase-2 nonrandomized prospective clinical trial. BMC Cancer. 2017 Nov 17;17(1):771. doi: 10.1186/s12885-017-3730-6.
Janky R, Binda MM, Allemeersch J, Van den Broeck A, Govaere O, Swinnen JV, Roskams T, Aerts S, Topal B. Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinoma. BMC Cancer. 2016 Aug 12;16:632. doi: 10.1186/s12885-016-2540-6.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HIPCUpp-trial
Identifier Type: -
Identifier Source: org_study_id